Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118


Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals.

van Zeventer IA, de Graaf AO, Wouters HJCM, van der Reijden BA, van der Klauw MM, de Witte T, Jonker MA, Malcovati L, Jansen JH, Huls G.

Blood. 2020 Apr 2;135(14):1161-1170. doi: 10.1182/blood.2019004362.


Association of vitamin B12, methylmalonic acid, and functional parameters.

Wolffenbuttel BHR, Wouters HJCM, de Jong WHA, Huls G, van der Klauw MM.

Neth J Med. 2020 Feb;78(1):10-24.


Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Micheaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Leukemia. 2020 Feb 4. doi: 10.1038/s41375-020-0725-0. [Epub ahead of print]


Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia.

In 't Hout FEM, Gerritsen M, Bullinger L, van der Reijden BA, Huls G, Vellenga E, Jansen JH.

Haematologica. 2019 Dec 19. pii: haematol.2019.232827. doi: 10.3324/haematol.2019.232827. [Epub ahead of print] No abstract available.


WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage.

de Jong MRW, Langendonk M, Reitsma B, Herbers P, Nijland M, Huls G, van den Berg A, Ammatuna E, Visser L, van Meerten T.

Cancers (Basel). 2019 Nov 7;11(11). pii: E1743. doi: 10.3390/cancers11111743.


Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern.

Berger G, Gerritsen M, Yi G, Koorenhof-Scheele TN, Kroeze LI, Stevens-Kroef M, Yoshida K, Shiraishi Y, van den Berg E, Schepers H, Huls G, Mulder AB, Ogawa S, Martens JHA, Jansen JH, Vellenga E.

Blood Adv. 2019 Oct 22;3(20):3111-3122. doi: 10.1182/bloodadvances.2019000518.


Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield.

Montes de Jesus FM, Kwee TC, Kahle XU, Nijland M, van Meerten T, Huls G, Dierckx RAJO, Rosati S, Diepstra A, van der Bij W, Verschuuren EAM, Glaudemans AWJM, Noordzij W.

Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):529-536. doi: 10.1007/s00259-019-04481-7. Epub 2019 Aug 24.


CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.

Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T.

Cancer Immunol Res. 2019 Oct;7(10):1663-1671. doi: 10.1158/2326-6066.CIR-18-0781. Epub 2019 Aug 13.


Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.

Eisenga MF, De Jong MA, Van der Meer P, Leaf DE, Huls G, Nolte IM, Gaillard CAJM, Bakker SJL, De Borst MH.

PLoS Med. 2019 Jun 6;16(6):e1002818. doi: 10.1371/journal.pmed.1002818. eCollection 2019 Jun.


Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements.

Kahle XU, Hovingh M, Noordzij W, Seitz A, Diepstra A, Visser L, van den Berg A, van Meerten T, Huls G, Boellaard R, Kwee TC, Nijland M.

Eur Radiol. 2019 Nov;29(11):6018-6028. doi: 10.1007/s00330-019-06178-9. Epub 2019 Apr 26.


Multidimensional radar dot-plots, do we need it for the screening of acute promyelocytic leukemia?

Ammatuna E, Huls G.

Ann Hematol. 2019 Jul;98(7):1793-1794. doi: 10.1007/s00277-019-03693-z. Epub 2019 Apr 25. No abstract available.


Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.

Hilberink J, Hazenberg C, van den Berg E, Mulder A, Schuringa JJ, van der Helm L, de Groot M, Choi G, de Bock GH, Vellenga E, Ammatuna E, Huls G.

Leuk Res. 2019 May;80:33-39. doi: 10.1016/j.leukres.2019.03.004. Epub 2019 Mar 18.


10-day vs 5-day decitabine: equivalence cannot be concluded.

Huls G, Suciu S, Wijermans P, Kicinski M, Lübbert M.

Lancet Haematol. 2019 Apr;6(4):e177. doi: 10.1016/S2352-3026(19)30024-9. No abstract available.


Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.

de Kort EA, de Lil HS, Bremmers MEJ, van Groningen LFJ, Blijlevens NMA, Huls G, Brüggemann RJM, van Dorp S, van der Velden WJFM.

PLoS One. 2019 Mar 21;14(3):e0213913. doi: 10.1371/journal.pone.0213913. eCollection 2019.


Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.

He Y, Bouwstra R, Wiersma VR, de Jong M, Jan Lourens H, Fehrmann R, de Bruyn M, Ammatuna E, Huls G, van Meerten T, Bremer E.

Nat Commun. 2019 Feb 1;10(1):533. doi: 10.1038/s41467-018-08013-z.


Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.

Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ, Sinnige H, Hodossy B, Graux C, Kooy RVM, de Weerdt O, Breems D, Klein S, Kuball J, Deeren D, Terpstra W, Vekemans MC, Ossenkoppele GJ, Vellenga E, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Blood. 2019 Mar 28;133(13):1457-1464. doi: 10.1182/blood-2018-10-879866. Epub 2019 Jan 10.


Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.

Montes de Jesus FM, Kwee TC, Nijland M, Kahle XU, Huls G, Dierckx RAJO, van Meerten T, Gheysens O, Dierickx D, Vergote V, Noordzij W, Glaudemans AWJM.

Crit Rev Oncol Hematol. 2018 Dec;132:27-38. doi: 10.1016/j.critrevonc.2018.09.007. Epub 2018 Sep 19.


Active smoking and macrocytosis in the general population: Two population-based cohort studies.

Eisenga MF, Wouters HJCM, Kieneker LM, van der Klauw MM, van der Meer P, Wolffenbuttel BHR, Gaillard CAJM, Kootstra-Ros JE, Touw DJ, Huls G, Bakker SJL.

Am J Hematol. 2019 Feb;94(2):E45-E48. doi: 10.1002/ajh.25346. Epub 2018 Nov 27. No abstract available.


TCF4 promotes erythroid development.

In 't Hout FEM, van Duren J, Monteferrario D, Brinkhuis E, Mariani N, Westers TM, Chitu D, Nikoloski G, van de Loosdrecht AA, van der Reijden BA, Jansen JH, Huls G.

Exp Hematol. 2019 Jan;69:17-21.e1. doi: 10.1016/j.exphem.2018.10.002. Epub 2018 Oct 10.


Association of anemia with health-related quality of life and survival: a large population-based cohort study.

Wouters HJCM, van der Klauw MM, de Witte T, Stauder R, Swinkels DW, Wolffenbuttel BHR, Huls G.

Haematologica. 2019 Mar;104(3):468-476. doi: 10.3324/haematol.2018.195552. Epub 2018 Oct 11.


Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones.

de Boer B, Prick J, Pruis MG, Keane P, Imperato MR, Jaques J, Brouwers-Vos AZ, Hogeling SM, Woolthuis CM, Nijk MT, Diepstra A, Wandinger S, Versele M, Attar RM, Cockerill PN, Huls G, Vellenga E, Mulder AB, Bonifer C, Schuringa JJ.

Cancer Cell. 2018 Oct 8;34(4):674-689.e8. doi: 10.1016/j.ccell.2018.08.014. Epub 2018 Sep 20.


Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrózek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Møller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G.

Cancer Med. 2018 Sep;7(9):4447-4455. doi: 10.1002/cam4.1733. Epub 2018 Aug 16.


Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M.

Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7.


The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2.

Riley LG, Heeney MM, Rudinger-Thirion J, Frugier M, Campagna DR, Zhou R, Hale GA, Hilliard LM, Kaplan JA, Kwiatkowski JL, Sieff CA, Steensma DP, Rennings AJ, Simons A, Schaap N, Roodenburg RJ, Kleefstra T, Arenillas L, Fita-Torró J, Ahmed R, Abboud M, Bechara E, Farah R, Tamminga RYJ, Bottomley SS, Sanchez M, Huls G, Swinkels DW, Christodoulou J, Fleming MD.

Haematologica. 2018 Dec;103(12):2008-2015. doi: 10.3324/haematol.2017.182659. Epub 2018 Jul 19.


DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4+CD25high FOXP3+ Regulatory T Cells but Does Not Affect Their Suppressive Capacity.

Landman S, Cruijsen M, Urbano PCM, Huls G, van Erp PEJ, van Rijssen E, Joosten I, Koenen HJPM.

J Immunol Res. 2018 Apr 15;2018:4973964. doi: 10.1155/2018/4973964. eCollection 2018.


GFI1 is required for RUNX1/ETO positive acute myeloid leukemia.

Marneth AE, Botezatu L, Hönes JM, Israël JCL, Schütte J, Vassen L, Lams RF, Bergevoet SM, Groothuis L, Mandoli A, Martens JHA, Huls G, Jansen JH, Dührsen U, Berg T, Möröy T, Wichmann C, Lo MC, Zhang DE, van der Reijden BA, Khandanpour C.

Haematologica. 2018 Sep;103(9):e395-e399. doi: 10.3324/haematol.2017.180844. Epub 2018 Apr 19. No abstract available.


Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.

Alkhawtani RHM, Noordzij W, Glaudemans AWJM, van Rijn RS, van der Galiën HT, Balink H, Nijland M, Adams HJA, Huls G, van Meerten T, Kwee TC.

Nucl Med Commun. 2018 Jun;39(6):572-578. doi: 10.1097/MNM.0000000000000840.


Active Smoking and Hematocrit and Fasting Circulating Erythropoietin Concentrations in the General Population.

Eisenga MF, Kieneker LM, Touw DJ, Nolte IM, van der Meer P, Huls G, Gaillard CAJM, Bakker SJL.

Mayo Clin Proc. 2018 Mar;93(3):337-343. doi: 10.1016/j.mayocp.2018.01.005.


Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.

de Jong MRW, Visser L, Huls G, Diepstra A, van Vugt M, Ammatuna E, van Rijn RS, Vellenga E, van den Berg A, Fehrmann RSN, van Meerten T.

PLoS One. 2018 Feb 28;13(2):e0193098. doi: 10.1371/journal.pone.0193098. eCollection 2018.


Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma.

Nijland M, van Meerten T, Seitz A, Huls G, Kibbelaar R, Visser L, van den Berg A, Diepstra A.

Ann Hematol. 2018 May;97(5):905-907. doi: 10.1007/s00277-018-3233-9. Epub 2018 Jan 11. No abstract available.


CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.

van Bommel PE, He Y, Schepel I, Hendriks MAJM, Wiersma VR, van Ginkel RJ, van Meerten T, Ammatuna E, Huls G, Samplonius DF, Helfrich W, Bremer E.

Oncoimmunology. 2017 Oct 31;7(2):e1386361. doi: 10.1080/2162402X.2017.1386361. eCollection 2018.


Efficacy of antithymocyte globulin as first-line treatment for aplastic anemia-a single-center experience.

van Zeventer IA, Schreurs JWGM, van den Berg E, Mulder AB, Vellenga E, Huls G, de Groot MR.

Ann Hematol. 2018 Apr;97(4):727-730. doi: 10.1007/s00277-017-3201-9. Epub 2017 Dec 16. No abstract available.


Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice.

Cany J, Roeven MWH, Hoogstad-van Evert JS, Hobo W, Maas F, Franco Fernandez R, Blijlevens NMA, van der Velden WJ, Huls G, Jansen JH, Schaap NPM, Dolstra H.

Blood. 2018 Jan 11;131(2):202-214. doi: 10.1182/blood-2017-06-790204. Epub 2017 Nov 14.


Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T; EUMDS Steering Committee.

Haematologica. 2018 Jan;103(1):69-79. doi: 10.3324/haematol.2017.171884. Epub 2017 Nov 9.


Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease.

Steinbach G, Hockenbery DM, Huls G, Furlong T, Myerson D, Loeb KR, Fann JR, Castilla-Llorente C, McDonald GB, Martin PJ.

PLoS One. 2017 Aug 17;12(8):e0183284. doi: 10.1371/journal.pone.0183284. eCollection 2017.


Clonal evolution in myelodysplastic syndromes.

da Silva-Coelho P, Kroeze LI, Yoshida K, Koorenhof-Scheele TN, Knops R, van de Locht LT, de Graaf AO, Massop M, Sandmann S, Dugas M, Stevens-Kroef MJ, Cermak J, Shiraishi Y, Chiba K, Tanaka H, Miyano S, de Witte T, Blijlevens NMA, Muus P, Huls G, van der Reijden BA, Ogawa S, Jansen JH.

Nat Commun. 2017 Apr 21;8:15099. doi: 10.1038/ncomms15099.


Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients.

Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, Leenders M, Bohme F, Kok N, Trilsbeek C, Paardekooper J, van der Waart AB, Westerweel PE, Snijders TJF, Cornelissen J, Bos G, Pruijt HFM, de Graaf AO, van der Reijden BA, Jansen JH, van der Meer A, Huls G, Cany J, Preijers F, Blijlevens NMA, Schaap NM.

Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. doi: 10.1158/1078-0432.CCR-16-2981. Epub 2017 Mar 9.


Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.

Langemeijer SM, Mariani N, Knops R, Gilissen C, Woestenenk R, de Witte T, Huls G, van der Reijden BA, Jansen JH.

PLoS One. 2016 Nov 30;11(11):e0165582. doi: 10.1371/journal.pone.0165582. eCollection 2016.


Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.

van der Helm LH, Berger G, Diepstra A, Huls G, Vellenga E.

Br J Haematol. 2017 Sep;178(5):810-812. doi: 10.1111/bjh.14166. Epub 2016 Jul 19. No abstract available.


Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Versluis J, In 't Hout FE, Devillier R, van Putten WL, Manz MG, Vekemans MC, Legdeur MC, Passweg JR, Maertens J, Kuball J, Biemond BJ, Valk PJ, van der Reijden BA, Meloni G, Schouten HC, Vellenga E, Pabst T, Willemze R, Löwenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen JJ.

Leukemia. 2017 Jan;31(1):26-33. doi: 10.1038/leu.2016.183. Epub 2016 Jun 24.


Severe Ankyrin-R deficiency results in impaired surface retention and lysosomal degradation of RhAG in human erythroblasts.

Satchwell TJ, Bell AJ, Hawley BR, Pellegrin S, Mordue KE, van Deursen CT, Braak NH, Huls G, Leers MP, Overwater E, Tamminga RY, van der Zwaag B, Fermo E, Bianchi P, van Wijk R, Toye AM.

Haematologica. 2016 Sep;101(9):1018-27. doi: 10.3324/haematol.2016.146209. Epub 2016 May 31.


Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.

Cruijsen M, Hobo W, van der Velden WJFM, Bremmers MEJ, Woestenenk R, Bär B, Falkenburg JHF, Kester M, Schaap NPM, Jansen J, Blijlevens NNM, Dolstra H, Huls G.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1000-1008. doi: 10.1016/j.bbmt.2016.02.003. Epub 2016 Feb 6.


Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.

Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW; EORTC Leukemia Group and the German MDS Study Group.

Ann Hematol. 2016 Jan;95(2):191-9. doi: 10.1007/s00277-015-2547-0. Epub 2015 Nov 23.


Allelic Mutations of KITLG, Encoding KIT Ligand, Cause Asymmetric and Unilateral Hearing Loss and Waardenburg Syndrome Type 2.

Zazo Seco C, Serrão de Castro L, van Nierop JW, Morín M, Jhangiani S, Verver EJ, Schraders M, Maiwald N, Wesdorp M, Venselaar H, Spruijt L, Oostrik J, Schoots J; Baylor-Hopkins Center for Mendelian Genomics, van Reeuwijk J, Lelieveld SH, Huygen PL, Insenser M, Admiraal RJ, Pennings RJ, Hoefsloot LH, Arias-Vásquez A, de Ligt J, Yntema HG, Jansen JH, Muzny DM, Huls G, van Rossum MM, Lupski JR, Moreno-Pelayo MA, Kunst HP, Kremer H.

Am J Hum Genet. 2015 Nov 5;97(5):647-60. doi: 10.1016/j.ajhg.2015.09.011. Epub 2015 Oct 29.


Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.

Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.


Azacitidine in AML: a treatment option?

Huls G.

Blood. 2015 Jul 16;126(3):283-4. doi: 10.1182/blood-2015-06-648071.


Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.

Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Ossenkoppele GJ, Löwenberg B, Jongen-Lavrencic M.

Leukemia. 2016 Jan;30(1):24-31. doi: 10.1038/leu.2015.188. Epub 2015 Jul 17.


Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells.

Te Boome LC, Mansilla C, van der Wagen LE, Lindemans CA, Petersen EJ, Spierings E, Thus KA, Westinga K, Plantinga M, Bierings M, Broers AE, Cuijpers ML, van Imhoff GW, Janssen JJ, Huisman C, Zeerleder S, Huls G, Boelens JJ, Wulffraat NM, Slaper-Cortenbach IC, Kuball J.

Leukemia. 2015 Sep;29(9):1839-46. doi: 10.1038/leu.2015.89. Epub 2015 Apr 3.


Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B; HOVON; SAKK Leukemia Groups.

Leukemia. 2015 May;29(5):1041-50. doi: 10.1038/leu.2014.332. Epub 2014 Nov 27.


High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions.

in 't Hout FE, van der Reijden BA, Monteferrario D, Jansen JH, Huls G.

Haematologica. 2014 Dec;99(12):e257-9. doi: 10.3324/haematol.2014.110437. Epub 2014 Aug 22. No abstract available.

Supplemental Content

Support Center